Please assess the completion status of the following clinical trial:

Trial Title: Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective coronary artery bypass grafting operation (CABG)~* decreased left ventricular (LV) systolic function (EF LV ≤ 50%)~* Age 18 to 85~* Signed informed consent~* Females with childbearing potential have to use appropriate contraceptive measures during the whole study period and 6 months after terminating exenatide infusion (hormonal contraception or double-barrier contraception for both partners)~Exclusion Criteria:~* allergy to exenatide~* allergy to insulin~* mental incapacity or language barrier~* use of incretin-based therapies \<3 months before inclusion in the study~* diabetic ketoacidosis~* established autonomic neuropathy~* history of acute pancreatitis or severe disease of digestive tract~* renal failure (preoperative creatinine ≥ 180 umol/l)~* liver failure (coagulation times more than 1.5 times higher without use of anticoagulants)~* cardiac surgical procedure on valve, thoracic aorta or MAZE procedure~* pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
- Control (Type: NO_INTERVENTION): Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).